• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rezolute Inc. (Amendment)

    2/13/24 4:31:18 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email
    SC 13G/A 1 rzlt13ga2024.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

     

    Rezolute, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

     

    76200L309

    (CUSIP Number)

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 76200L309

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization California

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 2,768,656

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 2,768,656
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,768,656

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.0%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 76200L309

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 2,768,656

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 2,768,656
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,768,656

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.0%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. 76200L309

     

    1.Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 2,768,656

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 2,768,656
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,768,656

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.0%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 76200L309

     

    1.Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 2,768,656

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 2,768,656
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,768,656

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.0%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     5 
    CUSIP No. 76200L309

     

    Item 1.

     

    (a)Name of Issuer

    Rezolute, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    275 Shoreline Drive, Suite 500, Redwood City, CA 94065

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Jon M. Plexico

     

    Timothy P. Lynch (collectively, the “Filers”)

     

    The General Partner is the general partner and investment adviser of the Partnership. Mr. Plexico and Mr. Lynch are the control persons of the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703-2767

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 76200L309

     

     6 
    CUSIP No. 76200L309
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 39,625,271 shares of Common Stock outstanding as of November 10, 2023, as reported in the Issuer’s Form 10-Q filed on November 13, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of the General Partner, Mr. Plexico and Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 76200L309

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 13, 2024

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch

    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch

    Timothy P. Lynch
    Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

     

     8 
    CUSIP No. 76200L309

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member

     

     
    /s/ Jon M. Plexico
     

     


    /s/ Timothy P. Lynch

     

     

     

    Get the next $RZLT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    8/2/2022$17.00Buy
    Canaccord Genuity
    6/15/2022$9.00Overweight
    Cantor Fitzgerald
    11/29/2021$30.00 → $17.00Buy
    Canaccord Genuity
    More analyst ratings

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

    REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr

    8/20/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute to Participate in the BTIG Virtual Biotechnology Conference

    REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia c

    7/22/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

    REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that the abstract titled "Preliminary Patient Demographics And Baseline Characteristics From A Phase 3 Study (sunRIZE) Of Ersodetug For Hypoglycemia Due To Congenital Hyperinsulinism: Trial In Progress" has been selected for a late-breaking presentation at ENDO 2025 taking place July 12-15, 2025 in San Francisco, CA, USA. "We are excited to share baseline data from the sunRIZE study, which will offer important insights into this population and its comparabilit

    7/9/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $RZLT
    SEC Filings

    View All

    Chief Medical Officer Roberts Brian Kenneth bought $10,939 worth of shares (2,500 units at $4.38), increasing direct ownership by 19% to 15,500 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    6/26/25 9:07:55 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $20,250 worth of shares (5,000 units at $4.05), increasing direct ownership by 2% to 268,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    6/24/25 12:41:19 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kim Young-Jin bought $3,999,999 worth of shares (1,230,769 units at $3.25) (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    6/23/25 9:38:51 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $10,939 worth of shares (2,500 units at $4.38), increasing direct ownership by 19% to 15,500 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    6/26/25 9:07:55 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $20,250 worth of shares (5,000 units at $4.05), increasing direct ownership by 2% to 268,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    6/24/25 12:41:19 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kim Young-Jin bought $3,999,999 worth of shares (1,230,769 units at $3.25) (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    6/23/25 9:38:51 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Rezolute, Inc. (0001509261) (Filer)

    8/20/25 6:06:33 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Rezolute Inc.

    EFFECT - Rezolute, Inc. (0001509261) (Filer)

    8/11/25 12:15:18 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rezolute Inc.

    SCHEDULE 13G/A - Rezolute, Inc. (0001509261) (Subject)

    8/6/25 12:11:01 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Leadership Updates

    Live Leadership Updates

    View All

    Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

    REDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. "We're thrilled to welcome Sunil to our leadership team at such a pivotal point as we advance ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "His proven track record of successfully bringing therapies to patients across multiple therapeutic areas, including four ultr

    8/20/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

    sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p

    5/13/25 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

    REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

    3/26/25 7:30:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Financials

    Live finance-specific insights

    View All

    Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

    Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re

    2/13/24 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports First Quarter Fiscal 2024 Results

    REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. "We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "We also anticipate completing enrollment this quarter for our o

    11/13/23 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

    REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023. "We are delighted that we are poised to initiate sunRIZE – our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 20

    9/14/23 4:05:00 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 10:04:23 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/13/24 5:31:40 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Rezolute with a new price target

    Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00

    11/5/24 6:25:51 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Rezolute with a new price target

    Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00

    8/27/24 7:36:43 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Rezolute with a new price target

    BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00

    7/17/24 7:55:53 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care